COMPANY
Cellergy Pharma
Founded in 2022, Cellergy Pharma is a privately held biotechnology company that is developing CAR T cell products for treating severe atopic allergic diseases. From company website Source · Oct 12, 2026
NIH awards 3
- NIH award 5R41AI188995-02 FY2026: $294,407 awarded for that fiscal year; activity R41 (STTR); PI MA, ZHENGYU; recipient as written: CELLERGY PHARMA, Wilmington, DE. Bispecific antibody targeting IgE-producing B cells source ↗
- NIH award 1R41AI188995-01 FY2025: $300,000 awarded for that fiscal year; activity R41 (STTR); PI MA, ZHENGYU; recipient as written: CELLERGY PHARMA, Wilmington, DE. Bispecific antibody targeting IgE-producing B cells source ↗
- NIH award 1R41AI177157-01A1 FY2024: $300,000 awarded for that fiscal year; activity R41 (STTR); PI MA, ZHENGYU; recipient as written: CELLERGY PHARMA, Wilmington, DE. Chimeric antigen receptor (CAR) T cell therapy fo source ↗
Funding and NIH signals
- NIH award NIH awarded $294K (STTR Phase I 5R41AI188995-02, continuation, notice May 28, 2026). NIH RePORTER 5R41AI188995-02 (May 28, 2026)
Evidence (1 event)
- May 28, 2026 · NIH RePORTER 5R41AI188995-02
Organization: CELLERGY PHARMA; City/State: Wilmington, DE; Project number: 5R41AI188995-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-28; FY total cost (award amount): 294407; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Bispecific antibody targeting IgE-producing B cells for treating allergic diseases; Organization type: Domestic For-Profits
- May 28, 2026 · NIH RePORTER 5R41AI188995-02